GlobeNewswire

Novavax to Highlight RSV Program Data at Two Upcoming Meetings

Del

GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.

Oral presentation details are as follows: 

IDWeek 2018 Meeting
     
Title:   Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
Presenter:   Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:   213. Late Breaker Oral Abstracts: Influenza and Vaccines 
Date and Time:   Saturday, October 6, 11:20 a.m. P.T.
Location:   Moscone Convention Center S 152-154
     
11th International Respiratory Syncytial Virus Symposium
     
Title:   Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant
Presenter:    Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc.
Session:   5. Advancements in RSV Vaccines
Date and Time:   Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T.
Location:   Omni Grove Park Inn
     
Title:    Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants
Presenter:   Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:    12. Maternal Immunity & Maternal Vaccination
Date:   Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T.
Location:    Omni Grove Park Inn
     

Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on Thursday, November 1, 11:30 a.m. – 12:30 p.m. E.T. and on Friday, November 2, 8:30 p.m. – 10:00 p.m. E.T. at the Omni Grove Park Inn.

Title:   Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization
Presenter:   Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc.
     
Title:   Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody
Presenter:    Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc.
     
Title:   In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine
Presenter:   Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc.
     
Title:   Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats
Presenter:   Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc.
     
Title:   Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection
Presenter:   Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:      

Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

NEP Group Acquires HDR, Expanding Its Broadcast and Media Solutions Capabilities in Europe and Worldwide25.6.2019 16:22:00 CESTPressemelding

PITTSBURGH, Pa. USA, June 25, 2019 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has signed a definitive agreement to purchase HDR Group, a full-service production partner headquartered in Stockholm, Sweden. The agreement became effective on June 17, 2019, and the deal is expected to close in early Q3 or Q4 of this year, conditional upon the approval of the Swedish Competition Authority. Prior to closing, NEP and HDR will continue to operate as separate and independent companies. HDR was founded in 2007 and today employs more than 100 employees who support clients in the live sports, entertainment and broadcast markets in Sweden, Norway, Denmark and Finland. The addition of HDR is consistent with NEP’s stated strategy to become the world leader in Broadcast Services and Media Solutions and increases NEP’s ability to serve its clients in the Nordic regi

Kim Crawford Wines Partners With US Open Tennis Championships25.6.2019 16:00:00 CESTPressemelding

No. 1-Selling Sauvignon Blanc in U.S. Becomes the Official Wine of the US Open Tennis Championships in New, Multi-Year Agreement WHITE PLAINS, N.Y. and MARLBOROUGH, New Zealand, June 25, 2019 (GLOBE NEWSWIRE) -- The United States Tennis Association (USTA) and Kim Crawford Wines today announced a new partnership that names Kim Crawford Wines as the official wine of the US Open Tennis Championships. The new, multi-year agreement commences with the 2019 Open. The No. 1-selling Sauvignon Blanci and leading New Zealand wine brandii in the U.S., Kim Crawford Wines will #ServeUpKim to US Open fans with a permanent brand presence on the grounds of the USTA Billie Jean King National Tennis Center. Kim Crawford will further support the partnership at retail locations across the country with impactful displays and an exciting sweepstakes, in which the winner will receive an all-expenses paid VIP experience at the 2020 US Open. The sweepstakes begins July 1 and ends August 31, during which consume

Painter 2020 Empowers Digital Artists to Achieve Their Perfect Vision25.6.2019 15:00:00 CESTPressemelding

New streamlined workflow, GPU-based brushing, and convenient color selection come together in the fastest Painter yet OTTAWA, June 25, 2019 (GLOBE NEWSWIRE) -- Painter 2020, the latest version of the industry’s most powerful and creative digital painting software, sets the standard for professional digital art on macOS and Windows. Allowing artists to realize their creative vision faster than ever, the new Painter® 2020 dramatically accelerates performance across virtually any system, while delivering a streamlined workflow, all-new brushes, enhanced color selection, and more. “Painter continues to redefine today’s professional digital art workflow,” said Chris Pierce, Senior Product Manager for Digital Arts at Corel. “Whether you’re running the latest hardware or your tried-and-true machine, this new version is an absolute game-changer. From experimenting with color to working with layers, the tools you rely on every day are now more accessible and intuitive.” “By leveraging GPU techn

Appian Announces Winners of its Annual Hackathon at Appian World25.6.2019 15:00:00 CESTPressemelding

RESTON, Va., June 25, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) congratulates the winners of the Appian World 2019 Hackathon. Participants were tasked with leveraging the Appian platform to showcase the effectiveness and speed of low-code development. Hundreds of registrations were narrowed down to three winners by a seasoned panel of judges including Black Girls Code Founder and CEO, Kimberly Bryant and Neil Ward-Dutton, IDC’s VP of AI and DX European Research Practices and Appian executives. Finalists attended Appian World 2019 in San Diego, CA where they showcased their solutions to the all-star panel of judges. The judges based their decisions on the originality of the idea underlying the application, how well that idea was executed by the developer, and the beneficial impact of the solution. The submissions, covering a variety of industries and use cases, all exemplified the power and simplicity of building enterprise applications on the Appian platform. The 2019 winners are:

XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa25.6.2019 14:45:00 CESTPressemelding

AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical Professor at the Icahn School of Medicine at Mount Sinai. She is one of few doctors in the nation board certified in Dermatology, Rheumatology and Internal Medicine. This will be the second study Chaired by Dr. Gottlieb involving bermekimab in HS and the third study conducted for the drug in HS. Dr. Gottlieb received an M.D.-Ph.D. from The Rockefeller University-Cornell University Medical College. Dr. Gottlieb founded the Tufts Dermatology residency program (which formally was shared with Boston University) and served as Chair of Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She also founded the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School where she serve

Mitsubishi Heavy Industries to Acquire Canadair Regional Jet Program from Bombardier Inc.25.6.2019 14:00:00 CESTPressemelding

MHI now positioned to transform and lead the underserved regional jet business , with bolster ed customer support services Key step in MHI’s strategy of expanding its aircraft business globally, with a mid-term focus on North America Completes Bombardier’s aerospace transformation and refocus on business aviation TOKYO and MONTRÉAL, June 25, 2019 (GLOBE NEWSWIRE) -- Mitsubishi Heavy Industries, Ltd (MHI) (TOKYO:7011) and Bombardier Inc (TSX: BBD.B) announced today they have entered into a definitive agreement, whereby MHI will acquire Bombardier’s regional jet program for a cash consideration of $550 million USD, payable to Bombardier upon closing, and the assumption by MHI of liabilities amounting to approximately $200 million USD. Under the agreement, Bombardier’s net beneficial interest in the Regional Aircraft Securitization Program (RASPRO), which is valued at approximately $180 million USD, will be transferred to MHI. Pursuant to the agreement, MHI will acquire the maintenance, s